⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CADL News
Candel Therapeutics, Inc. Common Stock
Candel Therapeutics Announces Proposed $100 Million Public Offering
globenewswire.com
CADL
Form 8-K
sec.gov
CADL
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
globenewswire.com
CADL
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
globenewswire.com
CADL
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CADL
Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad
prnewswire.com
ABBV
ACAD
ASTX
CADL
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
globenewswire.com
CADL
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
globenewswire.com
CADL
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
globenewswire.com
CADL
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
globenewswire.com
CADL